<DOC>
	<DOC>NCT00819104</DOC>
	<brief_summary>This is a randomised, open-label; parallel group, multicentric study comparing the efficacy and safety of fixed-dose-combinations of Metoprolol XL plus Amlodipine with individual components of the combination. SelomaxTM50/5 will also be compared with SelomaxTM 25/2.5 in lowering of BP (SBP and DBP) in Indian patients with essential hypertension.Male and female patients of essential hypertension aged between 18-80 years will be studied. The patients should not have a history of prior cardiovascular disease.</brief_summary>
	<brief_title>A Study to Compare the Efficacy, Safety and Tolerability of Selomax With Its Individual Components</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>Metoprolol</mesh_term>
	<criteria>Patients of hypertension (primary) , as judged by 2 BP measurements before randomisation Those who have given their written consent for the study. Patients of other forms of hypertension (other than primary) Those who have consistently BP &gt; /=180/120mmHg Patients with a prior history of chest pain, heart attacks, conduction defects and strokes. Patients of diabetes requiring insulin,asthma and kidney diseases.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>Primary hypertension</keyword>
	<keyword>Metoprolol XL</keyword>
	<keyword>Amlodipine</keyword>
</DOC>